# Vapogenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vapogenix

- Industry: Pharmaceuticals
- Headquarters: Houston, US
- Website: www.vapogenix.com
- Total disclosed funding: $5.1M
- Latest round: Series B (Mar 6, 2015)
- Investors on record: 2

## About

Vapogenix, Inc. develops innovative topical pain therapies using formulated volatile anesthetics, providing non-opioid solutions for effective pain management.Vapogenix, Inc. specializes in creating non-opioid pain relief therapies. Founded by Allen Burton and Danguole Altman, the company is headquartered in Houston, US. In August 2016, Vapogenix secured USD 7.98 mn in Series C funding from Pamoja Capital, raising its total funding to USD 7.98 mn and establishing a current company valuation of USD 28.17 mn.Vapogenix focuses on innovative, non-opioid topical pain therapies that utilize formulated volatile anesthetics. These products are designed for rapid onset and long-lasting effects to meet the needs of acute and chronic pain management. Targeting healthcare providers, pain management clinics, and consumers, Vapogenix operates primarily in the US and select international markets, providing alternatives to opioid treatments.The revenue structure of Vapogenix includes direct-to-consumer sales and B2B partnerships with healthcare providers and distribution channels. Their business transactions involve wholesale agreements with pharmacies and clinics, facilitating the distribution of topical therapies. Although specific pricing details are not disclosed, the revenue model encompasses retail pricing and partnership arrangements, with flagship products anticipated to significantly contribute to overall financial performance as they build brand recognition.Vapogenix plans to utilize the USD 7.98 mn raised in Series C financing to support upcoming product launches and market expansions. The company is focused on developing new topical pain relief products and aims to enter additional international markets by 2018. This funding will facilitate the design and promotion of these new offerings while enhancing distribution capabilities to reach a broader consumer base.

## Funding rounds

- Series B, Mar 6, 2015, $3M — Pamoja Capital, Green Park & Golf Ventures
- Series B, Dec 23, 2014, $2.1M — Pamoja Capital, Green Park & Golf Ventures

## Investors

- Pamoja Capital — Series B
- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Series B